Picture loading failed.

Pre-Made Lintuzumab biosimilar, Whole mAb Radiolabelled, Anti-CD33 Antibody: Anti-p67/SIGLEC3/SIGLEC-3 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Lintuzumab (SGN-33) is a humanized monoclonal antibody used in the treatment of cancer. The drug had been developed by Seattle Genetics as a treatment for acute myeloid leukemia (AML), a condition which results in the deaths of 9,000 people a year in the United States. Lintuzumab targets the CD33 protein, which is expressed in AML and other myeloproliferative diseases, but does not appear in abundance on normal cells.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-314-1mg 1mg Inquiry
GMP-Bios-ab-314-10mg 10mg Inquiry
GMP-Bios-ab-314-100mg 100mg Inquiry
GMP-Bios-ab-314-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Pre-Made Lintuzumab biosimilar, Whole mAb Radiolabelled, Anti-CD33 Antibody: Anti-p67/SIGLEC3/SIGLEC-3 therapeutic antibody
INN Name Lintuzumab
TargetCD33
FormatWhole mAb Radiolabelled
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusDiscontinued
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed1996
Year Recommended1997
CompaniesPDL BioPharma;Seattle Genetics
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedAcute myeloid leukaemia;Myelodysplastic syndromes
Development Techna